Last day of trading in BTA in Episurf Medical AB (publ) ("Episurf Medical" or the "Company") will be Monday, May 5, 2020 and stop day will be Wednesday, May 6, 2020.

Through the rights issue of shares, Episurf Medical raises approx. SEK 51 million before deduction of issue related costs.

The rights issue has now been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and last day of trading in Episurf Medical's BTA will be May 4, 2020. Stop day will be May 6, 2020. Shares are estimated to be delivered on the shareholders' account May 8, 2020.

Number of shares and share capital
Through partial registration of the rights issue Episurf Medical's share capital is increased by SEK 10,163,305.29 by issuing 34,849,033 class B shares. Given current share capital of SEK 43,315,859.79, Episurf Medical's share capital will thus amount to SEK 53,479,165.08 and the total number of shares will increase from 144,264,088 shares to 178,113,121 shares, divided into 971,024 class A shares and 177,142,097 class B shares after partial registration of the rights issue with the Swedish Companies Registration Office.

Advisers
Redeye AB and Zonda Partners AB act as financial advisers and DLA Piper Sweden KB acts as legal adviser in connection with the issue. Aqurat Fondkomission acts as the issuing agent in the Rights issue. 

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com (pal.ryfors@episurf.com)

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

https://news.cision.com/episurf/r/last-day-of-trading-in-paid-subscription-shares--sw--bta-,c3097988

https://mb.cision.com/Main/14691/3097988/1236907.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English